“Global Acute Myeloid Leukaemia set to grow to $1.8bn by 2025” says Visiongain report
31 October 2019
Visiongain has launched a new pharma report Global Acute Myeloid Leukaemia Market Report: Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib.
The global acute myeloid leukaemia market is estimated to grow at a CAGR of 13% in the first half of the forecast period. In 2018, the chemotherapy segment held 32% share of the global acute myeloid leukaemia market.
The lead analyst of the report commented "The growth of the acute myeloid leukemia market is estimated to be catalysed by opportunities in emerging markets with high potential due to improving healthcare infrastructure, unmet healthcare needs, rise in chronic diseases, and increased awareness.
The healthcare industry in the emerging nations is developing at a significant rate due to rise in demand for better healthcare services, significant investments by government to improve healthcare infrastructure, and an increase in the incidence of acute myeloid leukemia."
Leading companies featured in the report include Bristol-Myers Squibb Company, Celgene, Clavis Pharma ASA, Daiichi Sankyo, Eisai, GSK, Novartis, Roche, Sunesis Pharmaceuticals Teva and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.
About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Recent News
Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031
Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.
08 January 2021
Read
Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030
The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.
07 January 2021
Read
Visiongain Publishes Inactivated Vaccines Market Report 2020-2030
Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.
07 January 2021
Read
Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031
The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.
